Screener
Sionna Therapeutics SION Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income: | ||
| Interest income | 2,820 | 3,000 |
| Other income | — | 177 |
| Total other income | 2,820 | 3,177 |
| Net loss | $(26,779) | $(16,482) |
| Net loss per share, basic and diluted | $(0.60) | $(0.62) |
| Weighted-average common shares outstanding, basic and diluted | 44,921,984 | 26,596,059 |
| Comprehensive loss: |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's other income (expense)?
- Sionna Therapeutics (SION) reported other income (expense) of $2.82M in Q1 2026.
- How has Sionna Therapeutics's other income (expense) changed year-over-year?
- Sionna Therapeutics's other income (expense) decreased by 11.2% year-over-year, from $3.18M to $2.82M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Sionna Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude